for Jan 10, 2023 through Jan 16, 2023
🆕️⚡️⚡️Observational study of 24 US hospitals @CIDJournal
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 12, 2023
7 days of antibiotics appears effective for hospitalized patients with cUTI & bacteremia when antibiotics with comparable IV and oral bioavailability are administered#IDTwitter @BradSpellberg https://t.co/TxcDrTYac5 pic.twitter.com/qzP9lbwG1y
FANTASTIC⚡️⚡️
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 10, 2023
The evidence base for refraining from screening for or treating ASB in elderly is strong,but both practices remain prevalent
Bacteriuria in older adults triggers confusion in healthcare providers:A mindful pause to treat the worry #IDTwitter https://t.co/7ispdtFeFB pic.twitter.com/kOB5eGKkAc
New from @danlivorsi, @eliowa, @MGoto_Iowa:
— Infection Control & Hospital Epidemiology (@ICHEJournal) January 10, 2023
Tracking antimicrobial stewardship activities beyond days of therapy (DOT): Comparison of days of antibiotic spectrum coverage (DASC) and DOT at a single center
📄: https://t.co/4Ma7c1Th1v pic.twitter.com/mkNBxFuerp
🆕️⚡️⚡️ Retrospective analysis @jac_amr
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 11, 2023
Staphylococcus aureus bacteriuria: implications & management
Of 93 patients who had blood cultures taken, 6 cases of S. aureus bacteraemia, 4 associated with urological instrumentation
57% Rx with Abx
🌟Algorithm🌟 https://t.co/aGgETG3zyu pic.twitter.com/lKAZsyxXVb
Ibrexafungerp and oteseconazole have recently been FDA approved for treatment of vulvovaginal candidiasis. Superb summary of their role, highlighting both strengths and limitations of these novel agents, as well as important knowledge gaps. @CIDJournal https://t.co/pl7F8dYkcp pic.twitter.com/MYmzE97afh
— Paul Sax (@PaulSaxMD) January 16, 2023
Bacteriuria in older adults triggers confusion in healthcare providers.@EvaAmenta @rojosalta @bwtrautner suggest a mindful pause to treat the worry!
— Brad Langford (@BRxAD) January 11, 2023
New in @ASHE_Journalhttps://t.co/beUvvXjP3y pic.twitter.com/OjWxLtmpdu
Smart idea 💡
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 10, 2023
Beyond DOT
🆕️⚡️ @ICHEJournal @SHEA_Epi@eliowa et Al
Tracking antimicrobial stewardship activities beyond days of therapy (DOT): Comparison of days of antibiotic spectrum coverage (DASC) and DOT at a single center #IDtwitterhttps://t.co/JPj5vWE2hQ
Since I'm tweeting about Daptomycin
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 15, 2023
Five Interesting Things To Know About Daptomycin by
🌟 @IDstewardship
One more ?
Daptomycin (Cubicin) fda approved in December 2003
After 20 years,many non-ID colleagues I met think it's a new antibiotic 😂 #IDTwitter https://t.co/bCuTwJUZy3
Zinc is an essential mineral. Its long been known for its beneficial effects on immune health. On top of regulating immune function, zinc also aids in fighting infectious diseases like the flu and pneumonia. This is my favorite liquid zinc supplement: https://t.co/4fCzxbQixi #ad pic.twitter.com/yFE3alAOCm
— healthbot (@thehealthb0t) January 11, 2023
Bacteria sharing their antibiotic resistance genes is 1 of the main perpetuators of the ongoing AMR crisis. @vilhelmiina_h explores how Salmonella Typhimurium uses a plasmid to share resistance genes in the mammalian gut, even without antibiotic pressure. https://t.co/8hYGalAJA9
— ASM (@ASMicrobiology) January 13, 2023
Outer membrane vesicles (OMVs) may shield Klebsiella pneumoniae and act as decoys to polymyxin attack by reducing the export of proteins involved in polymyxin resistance, according to this #mSphere study: https://t.co/bldeX2t1DL pic.twitter.com/G1NNKsZwNZ
— ASM (@ASMicrobiology) January 16, 2023
#IDTwitter @ASHE_Journal @SHEA_Epi Huge thanks to the ASHE Team, SHEA, the reviewers and authors. The best is still to come...Antimicrobial Stewardship and Healthcare Epidemiology year in review, 2022: Celebrating successes while focusing on the future https://t.co/8rBbqB5CsE
— Gonzalo Bearman (@gonzalobearman) January 11, 2023
The former director of the National Institute of Allergy and Infectious Diseases writes off the permanent damage by myocarditis, shifts blame to ‘misinformation’.https://t.co/SkR7bkjGnG
— Rebel News USA (@RebelNews_USA) January 10, 2023
🆕️⚡️@CIDJournal @CLSI_LabNews@pranita_tamma @padstamundo @TheIDApprentice @romneyintn
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 10, 2023
Deconstructing the 2023 Clinical Laboratory and Standards Institute Revised Piperacillin-tazobactam Breakpoints Against Pseudomonas aeruginosa #IDTwitter https://t.co/BB2VKFyXVY pic.twitter.com/SzMtxnXBas
🔥Version 13 of the living WHO guideline on drugs for #COVID19 🔥@bmj_latest
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 13, 2023
⚡️Strong recommendation against sotrovimab in patients w non-severe COVID-19
⚡️🆕️recommendation :Paxlovid during pregnancy & breastfeeding
⚡️Molnupiravir: update in progress https://t.co/8Ud3Cdh20H pic.twitter.com/jjS2GsfT9j
The former director of the National Institute of Allergy and Infectious Diseases writes off the permanent damage by myocarditis, shifts blame to ‘misinformation’.https://t.co/eDceNrAxJt
— Rebel News (@RebelNewsOnline) January 10, 2023
New correspondence: 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protectionhttps://t.co/vQv2eu1gDF pic.twitter.com/r961loysqq
— The Lancet Infectious Diseases (@TheLancetInfDis) January 12, 2023
🆕️⚡️Retrospective cohort @InfectDis_Ther
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 11, 2023
High-dose daptomycin + IV fosfomycin improved the survival rate of pts with VRE-BSI compared to daptomycin alone
The benefit most pronounced for VRE with fosfomycin MIC ≤ 64 & pts with a low Pitt bacteremia scorehttps://t.co/UqZuTVbdCs pic.twitter.com/K62Lg6E7m7
🆕️⚡️Retrospective
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 11, 2023
Empiric antibiotic treatment with overall antimicrobial susceptibility 70% and above based on hospital cumulative antibiograms is associated with lower mortality & shorter length of ICU stay in sepsis patients with bacteremia in the EDhttps://t.co/O31LhiUJRm
Mycobacterium smegmatis has been at the vanguard of mycobacterial research. This #JBacteriology review outlines how the bacterium has advanced our understanding of mycobacteria, including by serving as a model for M. tuberculosis drug-target studies. https://t.co/Y2thUzkiH2 pic.twitter.com/AlOLYFwu2J
— ASM (@ASMicrobiology) January 12, 2023
A reminder in a large retrospective study of > 50, comparing paxlovid to no paxlovid, the control (no paxlovid) group had a risk of ALL hospitalization within 14 days of <1%, and a risk of ALL death within 28 days of <0.25%. The disease has changed.https://t.co/ht14OzZ8Ta pic.twitter.com/otATpoCcez
— Zain Chagla (@zchagla) January 15, 2023
🔥ACTIV-6 🔥
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 12, 2023
Among outpatients with mild to moderate COVID-19, treatment with 50 mg of fluvoxamine twice daily for 10 days, compared with placebo, did not improve time to sustained recovery #IDTwitter https://t.co/tsH3lnA75c pic.twitter.com/rZ3SdPf4qU
Antibiotics may increase risk of inflammatory bowel disease, study finds
— CIDRAP (@CIDRAP) January 10, 2023
The observational study found the associated risk increased with age and number of antibiotic courseshttps://t.co/i18hrqsSCF#AMR #AntibioticStewardship @CIDRAP_ASP pic.twitter.com/BHv11YEhqM
Super interesting ⚡️⚡️
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 14, 2023
Non antibiotic decolonization
A phase 2 RCT
B subtilis probiotic for intestinial Staph aureus decolonisation reduced S aureus colonisation in the intestine & the nares & thus might have clinical potential to lower infection rates https://t.co/pBRHZTJPAF pic.twitter.com/RoHjuEZHxS
The type VI secretion system (T6SS) effector, TseL, plays key roles in Pseudomonas aeruginosa host invasion & resistance to phagocytosis, & contributes to the emergence of novel epidemic strains of the bacterium. Learn more in @JournalSpectrum: https://t.co/aUjO8atAYd pic.twitter.com/GVBXNJvrID
— ASM (@ASMicrobiology) January 12, 2023
Zinc is an essential mineral. Its long been known for its beneficial effects on immune health. On top of regulating immune function, zinc also aids in fighting infectious diseases like the flu and pneumonia. This is my favorite liquid zinc supplement: https://t.co/4fCzxbQixi #ad pic.twitter.com/v9jVT3aYpb
— healthbot (@thehealthb0t) January 15, 2023
Costs of two vancomycin-resistant enterococci outbreaks in an academic hospital @ASHE_Journal
— Alex Sundermann, DrPH (@SundermannAJ) January 13, 2023
$514,111 from 2 outbreaks "from tests, closed beds (opportunity costs), cleaning, additional personnel, and patient isolation"
📄: https://t.co/WojpChDxP7 pic.twitter.com/FGLwK0CIkw
🆕️⚡️ @CIDJournal@jmmolinaparis
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 10, 2023
Cytomegalovirus (CMV) viremia in people with Human Immunodeficiency Virus (HIV): should we treat the CMV? Or the HIV? or Both? #IDTwitter https://t.co/6ILVjuAIGE
#Recoverytrial is currently testing 3 influenza therapies
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 13, 2023
Oseltamivir (an antiviral treatment)
Baloxavir (an antiviral treatment)
low dose corticosteroids, Dexamethasone
We will have definive answers soon #IDTwitter https://t.co/jJBypFYl81… https://t.co/iUamVgtsDH pic.twitter.com/gmK2rnWmoG
Principles for Ending Human Immunodeficiency Virus as an Epidemic in the United States: A Policy Paper of the Infectious Diseases Society of America and the HIV Medical Association
— Clinical Infectious Diseases (@CIDJournal) January 11, 2023
🆓 Freely Available
🔗 https://t.co/ac7A469tb3@HIVMA @IDSAInfo pic.twitter.com/WU0GsOgFy8
Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by #FDA for Amended Protocol Agreement of Phase 3 Clinical Study for #Bucillamine in the Treatment of #COVID19
— Revive Therapeutics (CSE: RVV, US: RVVTF) Official (@Revive_RVV) January 12, 2023
Read: https://t.co/pNkKez0L2l $RVV $RVVTF #Infectiousdiseases pic.twitter.com/49zXJyaNtC
🆕️⚡️⚡️Multicentre, prospective cluster randomised cross-over clinical trial
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 13, 2023
TDM guided dosing of voriconazole DID NOT show improved treatment outcome compared to the standard dosing regimen for treatment of invasive aspergillosis
Cc @FungalDoc #IDTwitterhttps://t.co/e84IUqNQwm
From @betrautner, @evaamenta: Evidence for not treating asymptomatic bacteriuria (ASB) in older adults is strong, but the practice remains. A mindful pause to apply evidenced-based assessments can clarify how to manage ASB https://t.co/y9HIdOGdGW
— ASHE Journal (@ASHE_Journal) January 11, 2023
👏First ever publication for @shaziaYousuf11 from her PhD study developing a core outcome set for hospital antimicrobial stewardship interventions👏🤩https://t.co/leuvI3gh0K @hsru_aberdeen
— Eilidh Duncan (@EilidhMDuncan) January 10, 2023
🆕️⚡️⚡️
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 13, 2023
Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B & influenza A(H3N2) infections in an historic cohort of 1,064 patients hospitalised during 2016-17 & influenza seasons UK
82% reduction of odds of in-patient deathhttps://t.co/tVeqDjNKMI
Study reveals multiple variants of XDR #typhoid in Pakistan
— CIDRAP (@CIDRAP) January 11, 2023
Genomic analysis of extensively drug-resistant typhoid isolates in Pakistan reveals numerous circulating XDR variantshttps://t.co/9FyJJwRkbY#AMR #AntibioticStewardship @CIDRAP_ASP
🆕️⚡️Systematic review & meta-analysis
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 16, 2023
6 RCTs (N=4,197)& 5 observational (N=1,156)
Efficacy & safety of SSRIs in #COVID19
Fluvoxamine remains a candidate pharmacotherapy for treating COVID-19 outpatients Medium-dose fluvox may be preferable over low-dosehttps://t.co/J1uLpMSRyn pic.twitter.com/tUNAOHpEuC
Bugs & β-lactamases? In #MRAJournal, researchers present the complete genome sequence of an Entomomonas strain isolated from larvae of the darkling beetle, Zophobas morio. The isolate was resistant to aztreonam & contained a novel class D β-lactamase gene. https://t.co/GL56l6JOrh pic.twitter.com/kuZrpGPgeh
— ASM (@ASMicrobiology) January 10, 2023
'Bacteriuria in older adults triggers confusion in healthcare providers: A mindful pause to treat the worry' - an #OpenAccess article by @ASHE_Journal #bacteriuria #olderadults #Mindfulness #healthcare https://t.co/zfAgz2KGN4 pic.twitter.com/0gS93IR8GE
— Cambridge Medicine and Health Sciences (@CUP_med_health) January 12, 2023
Antibiotic perseverance increases the risk of resistance development | Proceedings of the National Academy of Sciences https://t.co/MlCVODWFje
— Laura Piddock 💙 (@LauraPiddock) January 10, 2023
Three ways to combat antimicrobial resistance: https://t.co/NS1QKUQFQu
— Stop Superbugs (@TheUrgentNeed) January 10, 2023
The roles of bedside nurses in Japan in antimicrobial stewardship. @APIC #Japan #nurses #AntimicrobialResistance https://t.co/ruSQa4hkpI
— American Journal of Infection Control (@AJICJournal) January 16, 2023
A recent survey study of 551 primary care clinicians, 392 (71%) reported that they would prescribe antibiotics for asymptomatic bacteriuria ,eg scenario👇, shocking? #IDTwitter https://t.co/Gxwk4JNHut… https://t.co/f9lUtSos9v pic.twitter.com/6bIvz9YF2A
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 10, 2023
An attractive option?
— Antibiotic Steward Bassam Ghanem🆔🌟 (@ABsteward) January 12, 2023
🆕️⚡️⚡️Systematic Review and Meta-analysis @jamanetworkopen @ACasadevall1
Transfusion of COVID-19 convalescent plasma is associated with mortality benefit for patients who are immunocompromised and have #COVID19 #IDTwitter https://t.co/kzNGYYQiXx pic.twitter.com/HQ4FkztBEN
New correspondence: National case series of group A streptococcus pleural empyema in children: clinical and microbiological featureshttps://t.co/gp3R7t2quD
— The Lancet Infectious Diseases (@TheLancetInfDis) January 10, 2023
More evidence of high antibiotic use, low prevalence of bacterial co-infection in COVID-19 patients
— CIDRAP (@CIDRAP) January 11, 2023
Review provides further evidence that antibiotic use far exceeded the prevalence of bacterial co-infection with #COVID19https://t.co/UjkxQ2gU7A#AMR #AntibioticStewardship
Study says most long-COVID symptoms resolve by 1 year after mild cases, but experts not so sure
— CIDRAP (@CIDRAP) January 12, 2023
Many #LongCOVID patients have reported facing skepticism when seeking relief at their doctor's officehttps://t.co/Au3LQClweB#COVID19 @EricTopol @zalaly @Bob_Wachter pic.twitter.com/Mfw8dbDnk0
"Patients who received an appropriate initial antibiotic for bloodstream infections (BSIs) had a lower risk of death compared with those who received an inappropriate antibiotic..." https://t.co/ii3IYfHBXZ#AMR #antibioticresistance #SaveABX
— Accelerate (@AXDXNews) January 10, 2023
From @shiradoronMD and others @TuftsMedicine: Impact of antimicrobial use in dogs on antimicrobial resistance and shared flora with human owners https://t.co/ASwnEABdOM
— ASHE Journal (@ASHE_Journal) January 12, 2023
“#AntimicrobialStewardship programs were heavily involved in the COVID-19 response. Increased resourcing is needed to support core activities and pandemic-related work”https://t.co/VaDdFIT5Rl@DrKevinSchwartz @BRxAD @jackie_quirk #JACAMRNews #COVID19
— JAC-AMR (@jac_amr) January 16, 2023
#AntimicrobialResistance is a #OneHealth problem. We conducted a pilot study to see if resistant gut bacteria would be transferred between pet dogs and their owners when the dogs were given antibiotics. What we found was surprising. https://t.co/TLjkqzibyi
— Shira Doron MD (@ShiraDoronMD) January 10, 2023
Created by Cameron Forbes. Last updated January 31, 2023 at 05:16 EST.